#IORnews
Major awards to IOR and IOSI at SOHC 2025 in Basel.
Congratulations to Prof. Franco Cavalli, Prof. Davide Rossi, Prof. Anastasios Stathis, and Dr. Ghilardi for their well-deserved recognitions.
Read more: ior.usi.ch/events-news/...
Major awards to IOR and IOSI at SOHC 2025 in Basel.
Congratulations to Prof. Franco Cavalli, Prof. Davide Rossi, Prof. Anastasios Stathis, and Dr. Ghilardi for their well-deserved recognitions.
Read more: ior.usi.ch/events-news/...
November 25, 2025 at 1:22 PM
#IORnews
Major awards to IOR and IOSI at SOHC 2025 in Basel.
Congratulations to Prof. Franco Cavalli, Prof. Davide Rossi, Prof. Anastasios Stathis, and Dr. Ghilardi for their well-deserved recognitions.
Read more: ior.usi.ch/events-news/...
Major awards to IOR and IOSI at SOHC 2025 in Basel.
Congratulations to Prof. Franco Cavalli, Prof. Davide Rossi, Prof. Anastasios Stathis, and Dr. Ghilardi for their well-deserved recognitions.
Read more: ior.usi.ch/events-news/...
#IORnews
🎉 Congratulations to Dr. Lisa Pavinato, Postdoctoral Fellow in the Stem Cells and Cancer Lab led by Prof. Arianna Baggiolini on receiving the prestigious Brain & Behavior Research Foundation Young Investigator Grant!
🔗https://shorturl.at/BnMjx
🎉 Congratulations to Dr. Lisa Pavinato, Postdoctoral Fellow in the Stem Cells and Cancer Lab led by Prof. Arianna Baggiolini on receiving the prestigious Brain & Behavior Research Foundation Young Investigator Grant!
🔗https://shorturl.at/BnMjx
November 18, 2025 at 8:24 AM
#IORnews
🎉 Congratulations to Dr. Lisa Pavinato, Postdoctoral Fellow in the Stem Cells and Cancer Lab led by Prof. Arianna Baggiolini on receiving the prestigious Brain & Behavior Research Foundation Young Investigator Grant!
🔗https://shorturl.at/BnMjx
🎉 Congratulations to Dr. Lisa Pavinato, Postdoctoral Fellow in the Stem Cells and Cancer Lab led by Prof. Arianna Baggiolini on receiving the prestigious Brain & Behavior Research Foundation Young Investigator Grant!
🔗https://shorturl.at/BnMjx
#IORnews
On the occasion of the 75th anniversary of Switzerland’s recognition of the People’s Republic of China, IOR and IOSI will represent Swiss scientific excellence at a high-level event in Beijing dedicated to oncology research collaboration.
Read more: ior.usi.ch/events-news/...
On the occasion of the 75th anniversary of Switzerland’s recognition of the People’s Republic of China, IOR and IOSI will represent Swiss scientific excellence at a high-level event in Beijing dedicated to oncology research collaboration.
Read more: ior.usi.ch/events-news/...
November 12, 2025 at 2:19 PM
#IORnews
On the occasion of the 75th anniversary of Switzerland’s recognition of the People’s Republic of China, IOR and IOSI will represent Swiss scientific excellence at a high-level event in Beijing dedicated to oncology research collaboration.
Read more: ior.usi.ch/events-news/...
On the occasion of the 75th anniversary of Switzerland’s recognition of the People’s Republic of China, IOR and IOSI will represent Swiss scientific excellence at a high-level event in Beijing dedicated to oncology research collaboration.
Read more: ior.usi.ch/events-news/...
#IORnews
🎉 Congratulations to Dr. Jonas Van Lent on receiving the prestigious AFM-Téléthon Trampoline Grant!
This highly competitive grant supports promising early-career scientists developing bold and innovative projects in rare diseases.
🔗 shorturl.at/ghhNJ
🎉 Congratulations to Dr. Jonas Van Lent on receiving the prestigious AFM-Téléthon Trampoline Grant!
This highly competitive grant supports promising early-career scientists developing bold and innovative projects in rare diseases.
🔗 shorturl.at/ghhNJ
November 11, 2025 at 9:34 AM
#IORnews
🎉 Congratulations to Dr. Jonas Van Lent on receiving the prestigious AFM-Téléthon Trampoline Grant!
This highly competitive grant supports promising early-career scientists developing bold and innovative projects in rare diseases.
🔗 shorturl.at/ghhNJ
🎉 Congratulations to Dr. Jonas Van Lent on receiving the prestigious AFM-Téléthon Trampoline Grant!
This highly competitive grant supports promising early-career scientists developing bold and innovative projects in rare diseases.
🔗 shorturl.at/ghhNJ
#IORnews
🌊 Researchers from the IOR and the University of Galway in Ireland have identified a new natural compound from Irish marine life showing strong potential against an aggressive, hard-to-treat form of blood cancer.
Learn more: ior.usi.ch/events-news/...
🌊 Researchers from the IOR and the University of Galway in Ireland have identified a new natural compound from Irish marine life showing strong potential against an aggressive, hard-to-treat form of blood cancer.
Learn more: ior.usi.ch/events-news/...
November 6, 2025 at 8:30 AM
#IORnews
🌊 Researchers from the IOR and the University of Galway in Ireland have identified a new natural compound from Irish marine life showing strong potential against an aggressive, hard-to-treat form of blood cancer.
Learn more: ior.usi.ch/events-news/...
🌊 Researchers from the IOR and the University of Galway in Ireland have identified a new natural compound from Irish marine life showing strong potential against an aggressive, hard-to-treat form of blood cancer.
Learn more: ior.usi.ch/events-news/...
#IORnews
Congratulations to Prof. Davide Rossi, Group Leader at IOR and Deputy Head of Hematology at IOSI, on his appointment as Full Professor at USI within the Faculty of Biomedical Sciences.
🔗 ior.usi.ch/events-news/...
Congratulations to Prof. Davide Rossi, Group Leader at IOR and Deputy Head of Hematology at IOSI, on his appointment as Full Professor at USI within the Faculty of Biomedical Sciences.
🔗 ior.usi.ch/events-news/...
October 24, 2025 at 1:13 PM
#IORnews
Congratulations to Prof. Davide Rossi, Group Leader at IOR and Deputy Head of Hematology at IOSI, on his appointment as Full Professor at USI within the Faculty of Biomedical Sciences.
🔗 ior.usi.ch/events-news/...
Congratulations to Prof. Davide Rossi, Group Leader at IOR and Deputy Head of Hematology at IOSI, on his appointment as Full Professor at USI within the Faculty of Biomedical Sciences.
🔗 ior.usi.ch/events-news/...
#IORnews
IOR and IRB researchers (Theurillat & Cavalli labs) identify first-in-class inhibitors of FOXA1/FOXA2, long deemed “undruggable” drivers of prostate cancer.
➡️ Learn more: ior.usi.ch/events-news/...
IOR and IRB researchers (Theurillat & Cavalli labs) identify first-in-class inhibitors of FOXA1/FOXA2, long deemed “undruggable” drivers of prostate cancer.
➡️ Learn more: ior.usi.ch/events-news/...
October 23, 2025 at 8:42 AM
#IORnews
IOR and IRB researchers (Theurillat & Cavalli labs) identify first-in-class inhibitors of FOXA1/FOXA2, long deemed “undruggable” drivers of prostate cancer.
➡️ Learn more: ior.usi.ch/events-news/...
IOR and IRB researchers (Theurillat & Cavalli labs) identify first-in-class inhibitors of FOXA1/FOXA2, long deemed “undruggable” drivers of prostate cancer.
➡️ Learn more: ior.usi.ch/events-news/...
#IORnews
An international study conducted by the IOR Experimental Hematology Laboratory, led by Prof. Davide Rossi, offers a new perspective on the genetics of classical Hodgkin lymphoma.
Learn more: ior.usi.ch/events-news/...
An international study conducted by the IOR Experimental Hematology Laboratory, led by Prof. Davide Rossi, offers a new perspective on the genetics of classical Hodgkin lymphoma.
Learn more: ior.usi.ch/events-news/...
October 16, 2025 at 11:44 AM
#IORnews
An international study conducted by the IOR Experimental Hematology Laboratory, led by Prof. Davide Rossi, offers a new perspective on the genetics of classical Hodgkin lymphoma.
Learn more: ior.usi.ch/events-news/...
An international study conducted by the IOR Experimental Hematology Laboratory, led by Prof. Davide Rossi, offers a new perspective on the genetics of classical Hodgkin lymphoma.
Learn more: ior.usi.ch/events-news/...
#IORnews
IOR study led by Prof. Catapano uncovers key mechanisms driving prostate cancer stem cells and paves the way for innovative therapies.
🔗Learn more: ior.usi.ch/events-news/...
IOR study led by Prof. Catapano uncovers key mechanisms driving prostate cancer stem cells and paves the way for innovative therapies.
🔗Learn more: ior.usi.ch/events-news/...
September 19, 2025 at 12:34 PM
#IORnews
IOR study led by Prof. Catapano uncovers key mechanisms driving prostate cancer stem cells and paves the way for innovative therapies.
🔗Learn more: ior.usi.ch/events-news/...
IOR study led by Prof. Catapano uncovers key mechanisms driving prostate cancer stem cells and paves the way for innovative therapies.
🔗Learn more: ior.usi.ch/events-news/...
#IORnews
The Lab of Prof. J.P. Theurillat together with Dr. M. Bolis created the Prostate Cancer Atlas, a web-based platform that empowers the research community to explore, compare, and analyze data with unprecedented ease and flexibility.
🔗 short-url.org/1ecu9
www.youtube.com/watch?v=qTjJ...
The Lab of Prof. J.P. Theurillat together with Dr. M. Bolis created the Prostate Cancer Atlas, a web-based platform that empowers the research community to explore, compare, and analyze data with unprecedented ease and flexibility.
🔗 short-url.org/1ecu9
www.youtube.com/watch?v=qTjJ...
Prostate Cancer Atlas
YouTube video by Prostate Cancer Atlas
www.youtube.com
September 12, 2025 at 10:36 AM
#IORnews
The Lab of Prof. J.P. Theurillat together with Dr. M. Bolis created the Prostate Cancer Atlas, a web-based platform that empowers the research community to explore, compare, and analyze data with unprecedented ease and flexibility.
🔗 short-url.org/1ecu9
www.youtube.com/watch?v=qTjJ...
The Lab of Prof. J.P. Theurillat together with Dr. M. Bolis created the Prostate Cancer Atlas, a web-based platform that empowers the research community to explore, compare, and analyze data with unprecedented ease and flexibility.
🔗 short-url.org/1ecu9
www.youtube.com/watch?v=qTjJ...
#IORnews
A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL.
Learn more: tinyurl.com/ytybcbr8
A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL.
Learn more: tinyurl.com/ytybcbr8
September 9, 2025 at 8:26 AM
#IORnews
A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL.
Learn more: tinyurl.com/ytybcbr8
A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL.
Learn more: tinyurl.com/ytybcbr8
#IORnews
The Cancer Immunotherapy lab, led by Prof. A. Calcinotto, uncover a new immune–tumor interaction in ER+ breast cancer, opening the way for targeted therapies.
🔗Read more: ior.usi.ch/events-news/...
@calcinottolab.bsky.social
The Cancer Immunotherapy lab, led by Prof. A. Calcinotto, uncover a new immune–tumor interaction in ER+ breast cancer, opening the way for targeted therapies.
🔗Read more: ior.usi.ch/events-news/...
@calcinottolab.bsky.social
August 19, 2025 at 12:21 PM
#IORnews
The Cancer Immunotherapy lab, led by Prof. A. Calcinotto, uncover a new immune–tumor interaction in ER+ breast cancer, opening the way for targeted therapies.
🔗Read more: ior.usi.ch/events-news/...
@calcinottolab.bsky.social
The Cancer Immunotherapy lab, led by Prof. A. Calcinotto, uncover a new immune–tumor interaction in ER+ breast cancer, opening the way for targeted therapies.
🔗Read more: ior.usi.ch/events-news/...
@calcinottolab.bsky.social
#IORnews
Dr. Perez joins the IOR with a prestigious international grant on drug repurposing for healthy aging, now supported by the SNSF through the Money Follows Researcher agreement.
Read more: shorturl.at/pLKnm
Dr. Perez joins the IOR with a prestigious international grant on drug repurposing for healthy aging, now supported by the SNSF through the Money Follows Researcher agreement.
Read more: shorturl.at/pLKnm
August 7, 2025 at 8:38 AM
#IORnews
Dr. Perez joins the IOR with a prestigious international grant on drug repurposing for healthy aging, now supported by the SNSF through the Money Follows Researcher agreement.
Read more: shorturl.at/pLKnm
Dr. Perez joins the IOR with a prestigious international grant on drug repurposing for healthy aging, now supported by the SNSF through the Money Follows Researcher agreement.
Read more: shorturl.at/pLKnm
#IORnews
Among the 32 projects selected for funding in the first half of 2025 by the Swiss Cancer Research Foundation, are 3 research projects from the IOR, led by Prof. A. Alimonti, Prof. F. Bertoni and Prof. D. Rossi, focusing on lymphoma and prostate cancer.
Read more: shorturl.at/xqmAd
Among the 32 projects selected for funding in the first half of 2025 by the Swiss Cancer Research Foundation, are 3 research projects from the IOR, led by Prof. A. Alimonti, Prof. F. Bertoni and Prof. D. Rossi, focusing on lymphoma and prostate cancer.
Read more: shorturl.at/xqmAd
July 18, 2025 at 2:07 PM
#IORnews
Among the 32 projects selected for funding in the first half of 2025 by the Swiss Cancer Research Foundation, are 3 research projects from the IOR, led by Prof. A. Alimonti, Prof. F. Bertoni and Prof. D. Rossi, focusing on lymphoma and prostate cancer.
Read more: shorturl.at/xqmAd
Among the 32 projects selected for funding in the first half of 2025 by the Swiss Cancer Research Foundation, are 3 research projects from the IOR, led by Prof. A. Alimonti, Prof. F. Bertoni and Prof. D. Rossi, focusing on lymphoma and prostate cancer.
Read more: shorturl.at/xqmAd
#IORnews
New study from Prof. Jean-Philippe Theurillat’s Lab maps proteomic changes in prostate cancer progression, revealing overlooked drivers of aggressiveness.
🔗 Read the news: shorturl.at/wZWou
New study from Prof. Jean-Philippe Theurillat’s Lab maps proteomic changes in prostate cancer progression, revealing overlooked drivers of aggressiveness.
🔗 Read the news: shorturl.at/wZWou
July 3, 2025 at 8:07 AM
#IORnews
New study from Prof. Jean-Philippe Theurillat’s Lab maps proteomic changes in prostate cancer progression, revealing overlooked drivers of aggressiveness.
🔗 Read the news: shorturl.at/wZWou
New study from Prof. Jean-Philippe Theurillat’s Lab maps proteomic changes in prostate cancer progression, revealing overlooked drivers of aggressiveness.
🔗 Read the news: shorturl.at/wZWou
#IORnews
The 18th edition of the International Conference on Malignant Lymphoma (18-ICML), one of the most prestigious global events dedicated to lymphoid malignancies, concludes today after a week of intense scientific exchange and groundbreaking presentations.
🔗 ior.usi.ch/events-news/...
The 18th edition of the International Conference on Malignant Lymphoma (18-ICML), one of the most prestigious global events dedicated to lymphoid malignancies, concludes today after a week of intense scientific exchange and groundbreaking presentations.
🔗 ior.usi.ch/events-news/...
June 21, 2025 at 10:14 AM
#IORnews
The 18th edition of the International Conference on Malignant Lymphoma (18-ICML), one of the most prestigious global events dedicated to lymphoid malignancies, concludes today after a week of intense scientific exchange and groundbreaking presentations.
🔗 ior.usi.ch/events-news/...
The 18th edition of the International Conference on Malignant Lymphoma (18-ICML), one of the most prestigious global events dedicated to lymphoid malignancies, concludes today after a week of intense scientific exchange and groundbreaking presentations.
🔗 ior.usi.ch/events-news/...
#IORnews
🏆 Prof. F. Cavalli, President of the IOR Foundation, has been selected as the 2025 inductee in the Lymphoma category by the Giants of Cancer Care program, a prestigious recognition that honors the world’s most distinguished cancer researchers and clinicians.
➡️ Read more: shorturl.at/j7dbB
🏆 Prof. F. Cavalli, President of the IOR Foundation, has been selected as the 2025 inductee in the Lymphoma category by the Giants of Cancer Care program, a prestigious recognition that honors the world’s most distinguished cancer researchers and clinicians.
➡️ Read more: shorturl.at/j7dbB
June 20, 2025 at 8:22 AM
#IORnews
🏆 Prof. F. Cavalli, President of the IOR Foundation, has been selected as the 2025 inductee in the Lymphoma category by the Giants of Cancer Care program, a prestigious recognition that honors the world’s most distinguished cancer researchers and clinicians.
➡️ Read more: shorturl.at/j7dbB
🏆 Prof. F. Cavalli, President of the IOR Foundation, has been selected as the 2025 inductee in the Lymphoma category by the Giants of Cancer Care program, a prestigious recognition that honors the world’s most distinguished cancer researchers and clinicians.
➡️ Read more: shorturl.at/j7dbB
#IORnews
A Swiss study led by Prof. Davide Rossi opens the door to a new opportunity for patients with relapsed chronic lymphocytic leukemia.
📄 Read more: shorturl.at/bokQS
A Swiss study led by Prof. Davide Rossi opens the door to a new opportunity for patients with relapsed chronic lymphocytic leukemia.
📄 Read more: shorturl.at/bokQS
June 16, 2025 at 1:24 PM
#IORnews
A Swiss study led by Prof. Davide Rossi opens the door to a new opportunity for patients with relapsed chronic lymphocytic leukemia.
📄 Read more: shorturl.at/bokQS
A Swiss study led by Prof. Davide Rossi opens the door to a new opportunity for patients with relapsed chronic lymphocytic leukemia.
📄 Read more: shorturl.at/bokQS
#IORnews
🎉 Congratulations to Dr. Bianca Calì, research associate in our Molecular Oncology Lab, for receiving the prestigious SAKK/Astellas GU-Oncology Award 2025!
➡️ Discover more about her winning study: shorturl.at/N2UaB
🎉 Congratulations to Dr. Bianca Calì, research associate in our Molecular Oncology Lab, for receiving the prestigious SAKK/Astellas GU-Oncology Award 2025!
➡️ Discover more about her winning study: shorturl.at/N2UaB
May 26, 2025 at 9:02 AM
#IORnews
🎉 Congratulations to Dr. Bianca Calì, research associate in our Molecular Oncology Lab, for receiving the prestigious SAKK/Astellas GU-Oncology Award 2025!
➡️ Discover more about her winning study: shorturl.at/N2UaB
🎉 Congratulations to Dr. Bianca Calì, research associate in our Molecular Oncology Lab, for receiving the prestigious SAKK/Astellas GU-Oncology Award 2025!
➡️ Discover more about her winning study: shorturl.at/N2UaB
#IORnews
Jonas Van Lent receives the Children's Tumor Foundation's Young Investigator Award. Congrats @jonasvanlent.bsky.social !
Read more: shorturl.at/ObLS5
Jonas Van Lent receives the Children's Tumor Foundation's Young Investigator Award. Congrats @jonasvanlent.bsky.social !
Read more: shorturl.at/ObLS5
May 23, 2025 at 12:56 PM
#IORnews
Jonas Van Lent receives the Children's Tumor Foundation's Young Investigator Award. Congrats @jonasvanlent.bsky.social !
Read more: shorturl.at/ObLS5
Jonas Van Lent receives the Children's Tumor Foundation's Young Investigator Award. Congrats @jonasvanlent.bsky.social !
Read more: shorturl.at/ObLS5
#IORnews
IOR researchers uncover a new mechanism linking senescent cells and immune suppression in prostate cancer, paving the way for improved therapies.
➡️ Discover more: shorturl.at/7PBJ0
IOR researchers uncover a new mechanism linking senescent cells and immune suppression in prostate cancer, paving the way for improved therapies.
➡️ Discover more: shorturl.at/7PBJ0
April 11, 2025 at 11:58 AM
#IORnews
IOR researchers uncover a new mechanism linking senescent cells and immune suppression in prostate cancer, paving the way for improved therapies.
➡️ Discover more: shorturl.at/7PBJ0
IOR researchers uncover a new mechanism linking senescent cells and immune suppression in prostate cancer, paving the way for improved therapies.
➡️ Discover more: shorturl.at/7PBJ0
#IORnews
🧬 New bioinformatic tool developed at IOR: EasyCircR. This open-source R package maps circRNA-miRNA-mRNA interactions, unlocking insights into gene regulation & cancer research.
Discover more: shorturl.at/xjizN
🧬 New bioinformatic tool developed at IOR: EasyCircR. This open-source R package maps circRNA-miRNA-mRNA interactions, unlocking insights into gene regulation & cancer research.
Discover more: shorturl.at/xjizN
April 11, 2025 at 11:55 AM
#IORnews
🧬 New bioinformatic tool developed at IOR: EasyCircR. This open-source R package maps circRNA-miRNA-mRNA interactions, unlocking insights into gene regulation & cancer research.
Discover more: shorturl.at/xjizN
🧬 New bioinformatic tool developed at IOR: EasyCircR. This open-source R package maps circRNA-miRNA-mRNA interactions, unlocking insights into gene regulation & cancer research.
Discover more: shorturl.at/xjizN